The mission of the Habli Laboratory of Fetal growth and Developmental Origins of Adult Disease is to deliver healthier babies, free of adult diseases. This mission drives everything we do.   

Intra-Uterine Growth Restriction (IUGR) is the leading cause of perinatal morbidity and mortality. Compelling epidemiological and clinical studies have shown a strong association between IUGR and the subsequent development of adult disease. The long-term effects can have significant health and economic impacts; despite this there are currently no therapies for IUGR.

Our lab has taken on an extremely challenging project examining the cellular and molecular mechanisms of fetal programming in IUGR and tries to develop targeted therapy. We developed and validated a unique surgical IUGR mouse model that recapitulates human placental insufficiency. We are examining a novel placental therapy leading to fetal reprogramming and alleviating the risk of adult onset of disease such as metabolic syndrome. We further identified potential pathways for development of adult onset disease in growth-restricted newborn.